Metoprolol Stada

Metoprolol, the active ingredient in Metoprolol Stada, is a beta blocker presented as an oral tablet for oral use. It is employed to manage high blood pressure, relieve angina, and improve outcomes after heart attacks and in certain heart rhythm disorders.

GNH USA supplies Metoprolol Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches for global distribution. Customers benefit from reliable supply chains and responsive technical support.

Metoprolol is used in cardiovascular therapy to control heart rate and blood pressure across several conditions. - Hypertension: lowers systemic blood pressure and reduces cardiovascular risk. - Angina pectoris: decreases myocardial oxygen demand, relieving chest pain. - Myocardial infarction: improves survival and reduces recurrent ischemic events. - Heart failure: enhances left‑ventricular function and reduces hospitalisation. - Cardiac arrhythmias: stabilises abnormal heart rhythms, particularly atrial and ventricular tachyarrhythmias.

Metoprolol may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Fatigue: feeling unusually tired or weak. - Dizziness: light‑headedness, especially on standing. - Bradycardia: slower than normal heart rate. - Cold extremities: reduced blood flow to hands and feet. - Gastrointestinal upset: nausea or abdominal discomfort. - Depression: low mood or loss of interest.

Serious or Rare Side Effects: - Severe bradycardia: heart rate dropping to dangerously low levels. - Heart block: impaired electrical conduction in the heart. - Hypotension: significant drop in blood pressure causing faintness. - Bronchospasm: narrowing of airways, particularly in patients with asthma. - Allergic reactions: rash, itching, swelling, or anaphylaxis. - Cardiogenic shock: profound heart failure requiring emergency care.

Before initiating Metoprolol therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications. - Cardiac assessment: verify baseline heart rate and rhythm. - Blood pressure monitoring: check for hypotension during dose titration. - Renal/hepatic function: adjust dose if impairment is present. - Asthma/COPD caution: monitor for bronchospasm in reactive airway disease. - Discontinuation: avoid abrupt cessation to prevent rebound tachycardia. - Store at ambient temperature: keep below 25 °C in the original container, protected from moisture and light.

Metoprolol can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Non‑selective beta blockers: additive bradycardia and hypotension. - Calcium‑channel blockers (verapamil, diltiazem): profound heart‑rate slowing and AV‑block risk. - Class I antiarrhythmics (e.g., quinidine): increased risk of conduction disturbances. - Clonidine: abrupt withdrawal may cause severe hypertension. - Insulin or oral hypoglycemics: may mask hypoglycaemia symptoms.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: enhanced hypotensive effect. - Diuretics: potential for excessive blood‑pressure reduction. - NSAIDs: may diminish antihypertensive response. - Antidepressants (SSRIs, SNRIs): possible additive bradycardia. - Antidiabetic agents: monitor glucose control as beta‑blockade can affect metabolism.